Hormonal Optimization for Peak Performance

How Key Hormones Change with Age

Testosterone

In men, total testosterone typically peaks in the early-to-mid 20s and declines approximately 1–2% per year after age 30, according to the Massachusetts Male Aging Study — a landmark longitudinal study that followed 1,700 men over 17 years (Araujo et al., Journal of Clinical Endocrinology & Metabolism, 2007). By the time a man reaches 60, total testosterone levels may be 30–50% below their peak. This gradual decline — termed andropause or hypogonadism when clinically significant — is associated with reduced lean muscle mass, increased adiposity, decreased libido, cognitive dulling, fatigue, and mood changes.

In women, testosterone is also a critical hormone, though present in lower concentrations. It declines with age and falls sharply with menopause, contributing to reduced libido, muscle loss, and diminished energy. The Endocrine Society guidelines note that female androgen insufficiency — while still an evolving clinical entity — is associated with symptoms that meaningfully impact quality of life.

Estrogen

Estradiol, the most biologically active estrogen, plays essential roles in bone density, cardiovascular health, cognitive function, skin integrity, and mood regulation — in both women and men (in whom it is aromatized from testosterone). In women, the perimenopause transition — typically beginning in the mid-to-late 40s — is characterized by increasingly erratic estradiol levels before the sustained decline of menopause. The SWAN Study(Study of Women's Health Across the Nation), a multi-site longitudinal study funded by the NIH, documented the broad symptom burden accompanying this transition: hot flashes, sleep disruption, cognitive symptoms, and elevated cardiovascular risk.

Thyroid Hormones

The thyroid gland produces T4 (thyroxine) and T3 (triiodothyronine), which regulate metabolic rate across virtually every tissue. Subclinical hypothyroidism — elevated TSH with normal T4 — affects an estimated 3–8% of the general population and up to 15–18% of older women (Canaris et al., Archives of Internal Medicine, 2000). Symptoms including fatigue, cold intolerance, weight gain, cognitive fog, and elevated cholesterol are often attributed to aging rather than thyroid dysfunction, making comprehensive thyroid assessment essential.

DHEA and the Adrenal Axis

Dehydroepiandrosterone (DHEA) and its sulfate (DHEAS) are produced by the adrenal glands and serve as precursors to both testosterone and estrogen. DHEA peaks in the mid-20s and declines approximately 10% per decade — one of the most consistent age-related hormonal changes documented in human research (Orentreich et al.,Journal of Clinical Endocrinology & Metabolism, 1984). Low DHEAS is associated with increased cardiovascular risk, reduced immune function, and diminished physical performance.

Hormone Replacement: What the Evidence Says

The Women's Health Initiative (WHI) trial — published in JAMA in 2002 — raised concerns about hormone replacement therapy (HRT) and cardiovascular and breast cancer risk. However, subsequent re-analysis and decades of additional research have significantly refined those conclusions. The WHI enrolled primarily older women (average age 63) many years past menopause, using oral conjugated equine estrogen and synthetic medroxyprogesterone acetate — a combination that does not reflect current clinical practice.

The "timing hypothesis," developed from re-analyses by Rossouw et al. and supported by findings from the Kronos Early Estrogen Prevention Study (KEEPS) and Early versus Late Intervention Trial with Estradiol (ELITE), suggests that the cardiovascular and neuroprotective benefits of estrogen therapy are realized when initiated within 10 years of menopause onset or before age 60 — a window in which the vasculature retains estrogen receptor sensitivity.

The Menopause Society (formerly NAMS — North American Menopause Society) 2022 position statement concludes that for most healthy women under 60 or within 10 years of menopause onset, the benefits of hormone therapy for symptom management and disease prevention outweigh the risks. Current preferred formulations use body-identical (bioidentical) estradiol — transdermal or vaginal — and micronized progesterone when indicated.

For men, the Endocrine Society Clinical Practice Guidelines on Testosterone Therapy recommend evaluation for hypogonadism in men with consistent symptoms and confirmed low testosterone on two morning measurements, with treatment considered when both are present.

The Biomarker-First Approach

At CÉLURE, hormonal optimization begins with a comprehensive biomarker assessment — not with assumptions based on age or symptoms alone. A thorough hormonal panel typically includes total and free testosterone, estradiol, progesterone (when indicated), DHEAS, TSH, free T3, free T4, SHBG (sex hormone-binding globulin), LH, and FSH, alongside metabolic markers including fasting insulin, glucose, and lipid panel.

SHBG — the protein that binds and inactivates sex hormones in circulation — is particularly important. A patient with apparently adequate total testosterone may have significantly reduced free testosterone if SHBG is elevated. Without measuring both, the clinical picture is incomplete.

Protocol design then reflects the individual's full picture: their specific hormonal deficits, symptoms, metabolic baseline, cardiovascular risk, and goals. Hormonal interventions are not one-size-fits-all, and the difference between a well-designed protocol and an uninformed one can be clinically significant.